跳至主要内容
临床试验/NCT02368197
NCT02368197终止2 期

Prospective Randomized Trial Comparing Drug Eluting Balloon Versus Conventional Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas.

Shaare Zedek Medical Center1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2015年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
13
试验地点
1
主要终点
Restenosis rate

研究概览

简要总结

This study is designed to compare the safety and efficacy of paclitaxel-eluting balloon (DEB) versus conventional percutaneous transluminal angioplasty (PTA) for the treatment of hemodynamically significant recurrent cephalic arch stenosis in brachial cephalic fistulas in hemodialysis patients.

详细描述

The cephalic vein constitutes the major outflow conduit for radial- cephalic autogenous accesses and is the sole outflow conduit for brachial- cephalic autogenous accesses. The portion of the cephalic vein that becomes perpendicular in the region of the deltopectoral groove before its confluence with the axillary or subclavian vein,the cephalic arch, is prone to the development of hemodynamically significant stenosis which is usually treated with balloon angioplasty. Unfortunately restenosis due to angioplasty induced intimal hyperplasia is common and periodic repeated angioplasty is necessary to maintain patency.

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy which is used as an antiproliferative agent for the prevention of restenosis (recurrent narrowing) of blood vessels after balloon angioplasty caused by excessive intimal proliferation. It is locally delivered to the wall of the blood vessel during the dilatation using a paclitaxel eluting balloon.

Initial trials with these balloons have shown promising results in peripheral arteries and early encouraging results in dialysis access.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Upper limb dialysis access fistula
  • Angiographically demonstrated cephalic arch stenosis >50% within 6 months of last angioplasty using a non drug eluting balloon
  • Clinical evidence of hemodynamically significant stenosis: strong pulse and weak thrill on physical exam, prolonged bleeding from puncture sites, raised Kt/V, raised dialysis venous pressure

排除标准

  • Contrast allergy
  • Unable to give informed consent
  • Cephalic arch stent or stent graft
  • Life expectancy less then 6 months

研究组 & 干预措施

Standard balloon angioplasty

Active Comparator

Dilatation of stenosis with standard non drug eluting balloon catheter

干预措施: Balloon angioplasty (Bard Dorado) (Device)

Drug eluting balloon angioplasty

Experimental

Dilatation of stenosis with paclitaxel eluting balloon catheter

干预措施: paclitaxel (Cardionovum Legflow drug eluting balloon) (Drug)

结局指标

主要结局

Restenosis rate

时间窗: 6 months

Incidence of \>50% stenosis at the treatment site

次要结局

  • Post intervention lesion patency(Up to 12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anthony Verstandig

Dr

Shaare Zedek Medical Center

研究点 (1)

Loading locations...

相似试验